SAB Biotherapeutics (SABS) has an average rating of buy and mean price target of $11.33, according to analysts polled by FactSet.
What else is happening in Research?
Research
Craig Hallum Upgrades Backblaze to Buy From Hold, $16 Price Target
Craig Hallum Upgrades Backblaze to Buy From Hold, $16 Price Target
$BLZE
Research
Daiwa Downgrades JD.com to Hold From Buy, Adjusts Price Target to $27 From $47
JD.com (JD) has an average rating of overweight and mean price target of $39.89, according to analysts polled by FactSet.Price: $26.32, Change: $-0.70, Percent Change: -2.61%
$JD
Research
Daiwa Downgrades PDD to Hold From Buy, Adjusts Price Target to $80 From $145
PDD (PDD) has an average rating of overweight and mean price target of $118.72, according to analysts polled by FactSet.Price: $76.35, Change: $-1.77, Percent Change: -2.26%
$PDD